Prelude Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Prelude Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,944	Closed	-$38.6K	–	1281
2023 Q1	$38.6K	Sell	13,944 -3,400	-20%	-$7.13K	﹤0.01%	1018
2022 Q4	$31.2K	Hold	17,344	–	–	﹤0.01%	1159
2022 Q3	$37K	Buy	+17,344	New	+$43.6K	﹤0.01%	1247
2021 Q3	–	Sell	-49,500	Closed	-$500K	–	1922
2021 Q2	$500K	Buy	+49,500	New	+$536K	0.01%	949

Other funds holding NAUT

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

AEPLI

AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

Prelude Capital Management's NAUT Position: Q2 2023 in Review

Prelude Capital Management sold out of Nautilus Biotechnolgy (NAUT) in Q2 2023, closing a stake of 13,944 shares — an estimated $38.6K sold.

Prelude Capital Management first reported a position in NAUT in Q2 2021 and held it in 4 quarters. The position peaked at $500K in Q2 2021. 75 funds tracked by Wall St. Rank hold NAUT as of Q2 2023.

Prelude Capital Management reported no remaining Nautilus Biotechnolgy position as of Q2 2023 after selling out during the quarter.
Prelude Capital Management sold 13,944 Nautilus Biotechnolgy shares in Q2 2023, an estimated $38.6K.
Prelude Capital Management first reported a position in Nautilus Biotechnolgy in Q2 2021 and held it in 4 quarters.
Prelude Capital Management's Nautilus Biotechnolgy position peaked at $500K in Q2 2021.
75 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.